List of Excipients in Branded Drug MONOFERRIC

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacosmos Therapeutics Inc	MONOFERRIC	ferric derisomaltose	73594-9301	HYDROCHLORIC ACID	2029-03-25
Pharmacosmos Therapeutics Inc	MONOFERRIC	ferric derisomaltose	73594-9301	NITROGEN	2029-03-25
Pharmacosmos Therapeutics Inc	MONOFERRIC	ferric derisomaltose	73594-9301	SODIUM HYDROXIDE	2029-03-25
Pharmacosmos Therapeutics Inc	MONOFERRIC	ferric derisomaltose	73594-9301	WATER	2029-03-25
Pharmacosmos Therapeutics Inc	MONOFERRIC	ferric derisomaltose	73594-9305	HYDROCHLORIC ACID	2029-03-25
Pharmacosmos Therapeutics Inc	MONOFERRIC	ferric derisomaltose	73594-9305	NITROGEN	2029-03-25

Monoferric Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

Monoferric is an intravenous iron product containing ferric derisomaltose, a stable iron-carbohydrate complex supplied at 100 mg elemental iron per mL. Its commercial position is driven primarily by high-dose administration, reduced dosing frequency, and a simple ready-to-use formulation. The strongest excipient opportunities are therefore in stability enhancement, infusion compatibility, container systems, dilution platforms, and differentiated administration formats rather than in adding conventional formulation ingredients.

What is the Monoferric formulation?

Monoferric is a sterile, preservative-free intravenous solution. The U.S. product contains ferric derisomaltose equivalent to 100 mg elemental iron per mL. The labeled inactive ingredients are water for injection and sodium chloride. The solution has an acidic-to-near-neutral pH range and is supplied in single-dose vials containing 1,000 mg iron in 10 mL or 1,500 mg iron in 15 mL presentations.[1]

Attribute	Monoferric characteristic
Active pharmaceutical ingredient	Ferric derisomaltose
Iron concentration	100 mg elemental iron/mL
Route	Intravenous infusion
Primary dosage form	Sterile solution
Preservatives	None listed
Core excipients	Water for injection; sodium chloride
Administration	Dilution in 100-250 mL of 0.9% sodium chloride or 5% dextrose before infusion
Typical adult dosing	1,000 mg for patients below 50 kg; 1,500 mg for patients at least 50 kg, subject to labeling
U.S. approval	FDA approval in January 2020 under NDA 208171
Sponsor	Pharmacosmos A/S

The formulation is intentionally minimal. That limits excipient-related toxicity and simplifies regulatory review, but it also leaves commercial room for improved presentation, administration, and container compatibility.

What excipient functions are commercially relevant for Monoferric?

The most relevant excipient functions are physical stabilization, pH control, tonicity control, infusion compatibility, and protection from extractables and leachables.

Physical stabilization of the iron-carbohydrate complex

Ferric derisomaltose is a colloidal iron-carbohydrate complex rather than a conventional small-molecule solution. Its quality attributes include particle-size distribution, iron-core structure, carbohydrate shell characteristics, labile iron, aggregation, and free-iron release.

Potential excipient strategies include:

• Tight control of ionic strength using sodium chloride or alternative tonicity agents.
• Buffer systems that maintain pH without accelerating iron release.
• Complexation-control approaches that reduce labile iron during storage.
• Antioxidant systems, only where compatibility and safety are demonstrated.
• Low-shear manufacturing and filling processes that preserve colloidal integrity.

The commercial value is high because a formulation that maintains colloidal stability across temperature excursions could support broader distribution, reduced wastage, and alternative container formats.

pH and osmolality management

The label permits dilution in normal saline or 5% dextrose. This creates an opportunity to develop a formulation or administration kit with a defined final pH and osmolality profile.

A differentiated product could target:

• Lower infusion discomfort.
• Reduced risk of precipitation after dilution.
• Improved compatibility with commonly used infusion lines.
• Longer in-use stability after dilution.
• More predictable administration through ambulatory infusion devices.

Any change to pH, buffer, or tonicity would require comparative studies covering iron release, visible and subvisible particles, potency, sterility, and container compatibility. For an intravenous iron complex, conventional buffer selection is constrained because phosphate, citrate, acetate, and other multifunctional anions may interact with iron or alter colloidal behavior.

Compatibility with infusion materials

Infusion-system compatibility is a practical commercial issue. The product is diluted before administration, so the relevant system includes:

• Polyvinyl chloride and non-PVC bags.
• Polyolefin containers.
• Elastomeric stoppers.
• Infusion tubing.
• Inline filters.
• Syringes and transfer devices.
• Ambulatory infusion pumps.

A formulation or delivery package that demonstrates compatibility with a broader range of materials could reduce pharmacy preparation steps. The data package should assess adsorption, iron loss, particulate formation, discoloration, container integrity, and extractables and leachables under labeled storage and administration conditions.

What excipient strategies could differentiate a Monoferric competitor?

A competitor is unlikely to gain a strong position by replacing sodium chloride alone. The more defensible strategy is a coordinated formulation and presentation platform.

Ready-to-infuse presentation

Monoferric currently requires dilution before infusion under the U.S. label.[1] A ready-to-infuse bag or pharmacy-prepared kit could reduce preparation time and handling risk.

Potential commercial formats include:

Format	Commercial rationale	Principal development issue
Pre-diluted infusion bag	Eliminates dilution step	Stability after dilution and container compatibility
Dual-chamber bag	Separates concentrate from diluent until use	Device complexity and mixing validation
Prefilled syringe	Supports controlled transfer into an infusion bag	Viscosity, syringeability, and dose-volume constraints
Cartridge for infusion pump	Enables standardized administration	Adsorption and pump-material compatibility
Small-volume high-concentration vial	Reduces storage and handling volume	Local tolerability and infusion-line compatibility
Single-use administration kit	Combines vial, diluent, tubing, and transfer device	Combination-product and supply-chain requirements

A ready-to-infuse product would likely have greater commercial value than a conventional excipient substitution because it can change pharmacy workflow and total cost of administration.

Extended post-dilution stability

The current labeled dilution window creates a potential target for improvement. An excipient and container system that supports 24 to 48 hours of post-dilution stability could benefit centralized pharmacy operations, outpatient infusion centers, and hospital scheduling.

The development program should measure:

• Elemental iron concentration.
• Ferric derisomaltose molecular and colloidal integrity.
• Free or labile iron.
• Particle burden.
• Color and appearance.
• pH and osmolality.
• Sterility and container closure integrity.
• Compatibility with administration materials.

An extended-stability claim would need to distinguish chemical stability from microbiological beyond-use dating. The latter may be governed by pharmacy compounding rules and local practice standards rather than by the drug label alone.

Low-volume infusion

Monoferric already has a high iron concentration compared with many intravenous iron products. A competitor could pursue a lower-volume administration profile, but the principal limitation is tolerability and infusion rate rather than vial volume.

A lower-volume formulation could require:

• Higher iron concentration.
• Higher colloid concentration.
• Revised sodium chloride content.
• New osmolality and viscosity controls.
• Dedicated infusion-rate studies.
• Assessment of injection-site and systemic tolerability.

The opportunity is commercially attractive in outpatient settings, but it is technically more difficult than producing a pre-diluted version at the same concentration.

What formulations are protected or potentially protectable around Monoferric?

The commercially relevant protection categories are the iron-carbohydrate complex, composition parameters, manufacturing process, dosage regimen, and delivery presentation.

Core active-complex protection

Ferric derisomaltose is a complex drug substance with structural and process attributes that may be protected through patents covering:

• Iron-carbohydrate complex composition.
• Iron-to-carbohydrate ratios.
• Molecular-weight distribution.
• Preparation and purification methods.
• Control of labile iron.
• Stability and degradation characteristics.

These claims can create a higher barrier than ordinary small-molecule formulation claims because the active ingredient itself is a complex mixture or supramolecular structure.

Formulation patents

Potential formulation claims could cover:

• Specific pH ranges.
• Ionic strength or sodium chloride concentrations.
• Buffer-free formulations.
• Diluted infusion compositions.
• Specific container materials.
• Stability after dilution.
• Low-particle formulations.
• Ready-to-use infusion bags.
• Compatibility with infusion devices.

Formulation patents are strongest when they connect a defined composition to a measurable technical effect, such as reduced labile iron, improved stability, reduced particle formation, or longer in-use storage.

Method-of-use patents

Potential method-of-use protection may cover:

• High-dose iron replacement with one or two administrations.
• Treatment of iron-deficiency anemia in chronic kidney disease.
• Treatment in patients with inflammatory bowel disease or heart failure.
• Weight-based or hemoglobin-based dosing.
• Use in patients intolerant of oral iron.
• Reduced infusion frequency.

Method-of-use claims can affect prescribing and substitution even when a generic product obtains approval for the same active ingredient. Their practical strength depends on Orange Book listing, enforceability, labeling overlap, and whether the proposed generic label can omit the protected indication or dosing instruction.

What is the FDA and Orange Book status of Monoferric?

Monoferric was approved by FDA in January 2020 under NDA 208171 for iron-deficiency anemia in adults who have intolerance or an unsatisfactory response to oral iron, or who have chronic kidney disease.[1] The product is not a biologic and is not expected to follow the biosimilar pathway.

Regulatory issue	Assessment
FDA pathway	New drug application
NDA	208171
Product type	Intravenous iron complex
Biosimilar pathway	Not applicable
Likely generic pathway	ANDA, subject to FDA determination of pharmaceutical equivalence and bioequivalence
Orange Book relevance	Listed patents and exclusivity may affect ANDA approval and launch
Reference-product risk	Complex active ingredient and process similarity create technical and legal complexity

The Orange Book should be reviewed for the current patent and exclusivity entries because FDA listings can change through patent-listing updates, delistings, certifications, and litigation outcomes.[2] The relevant commercial question is not only whether Monoferric has listed patents, but whether those patents claim the drug substance, formulation, method of use, or manufacturing process.

When does Monoferric lose exclusivity?

Monoferric's core regulatory exclusivity began with its 2020 approval, but regulatory exclusivity and patent exclusivity operate on different timelines.

FDA exclusivity generally determines when an ANDA may be submitted or approved. Patent expiry and patent litigation determine whether a generic can launch before the nominal end of the patent term. For Monoferric, the principal risks are:

1. Paragraph IV certification against listed patents.
2. A 30-month stay following timely patent litigation.
3. Patent-term adjustment or patent-term extension.
4. Settlement agreements that establish an authorized or licensed generic entry date.
5. Non-listed process or manufacturing patents that may support separate litigation, although they may not block ANDA approval in the same way as Orange Book-listed patents.

Public patent records identify Pharmacosmos-related U.S. patent activity around iron-carbohydrate complexes and their manufacture. Exact expiration analysis requires review of the current Orange Book entry, USPTO term calculations, terminal disclaimers, and any patent-term adjustment. A nominal expiration date should not be treated as a launch date without checking those records.[2,3]

Which companies are challenging Monoferric?

The principal competitive threat is from generic manufacturers developing ferric derisomaltose or a therapeutically equivalent product. The relevant companies are those that:

• File an ANDA referencing NDA 208171.
• Submit a Paragraph IV certification.
• Seek a judgment of non-infringement or invalidity.
• Negotiate a license or settlement with Pharmacosmos.
• Develop an alternative intravenous iron complex rather than a direct generic.

A company-by-company litigation assessment should rely on PACER, FDA Paragraph IV litigation records, Orange Book updates, and SEC disclosures. No biosimilar competitor category applies because ferric derisomaltose is a non-biologic drug product.

What generic entry risks exist for Monoferric?

Generic entry is more complex than for a conventional aqueous small molecule. The key technical risks are equivalence and manufacturing reproducibility.

Active-complex equivalence

A generic applicant may need to demonstrate control of:

• Iron content.
• Iron oxidation state.
• Carbohydrate identity and distribution.
• Iron-to-carbohydrate ratio.
• Particle-size distribution.
• Molecular-weight distribution.
• Labile iron.
• Release profile.
• Immunogenicity or hypersensitivity-relevant attributes.

The FDA has issued product-specific guidance for certain complex injectable products, but the applicable requirements depend on the product and current agency guidance. For ferric derisomaltose, the evidentiary burden may include comparative physicochemical characterization and clinical or pharmacodynamic studies beyond standard small-molecule expectations.[4]

Manufacturing and IP barriers

Manufacturing is a central barrier because the commercial product depends on a reproducible iron-carbohydrate complex. Relevant barriers include:

• Control of carbohydrate starting material.
• Reaction temperature and pH.
• Iron loading and oxidation control.
• Purification and removal of low-molecular-weight species.
• Batch-to-batch colloidal consistency.
• Sterile filtration and filling.
• Container interaction.
• Analytical methods for complex attributes.

These barriers can support commercial value even when composition claims are vulnerable. A manufacturer with established iron-complex production and validated analytical methods may have a shorter development path than a conventional generic company.

How does Monoferric compare with competing intravenous iron products?

Product	Active ingredient	Typical dosing proposition	Formulation opportunity
Monoferric	Ferric derisomaltose	High-dose replacement, often one administration	Ready-to-infuse formats and extended post-dilution stability
Injectafer	Ferric carboxymaltose	High-dose replacement, commonly one or two administrations	Alternative complex, concentration, and administration system
Feraheme	Ferumoxytol	Two-dose course or specific dosing schedules	Lower-volume administration and device compatibility
Venofer	Iron sucrose	Multiple smaller doses	Scheduling reduction and high-dose alternatives
Ferrlecit	Sodium ferric gluconate	Repeated administration, particularly in dialysis	Convenience and pharmacy workflow

Monoferric competes on dose consolidation and administration burden. An excipient strategy that reduces pharmacy preparation or permits a more flexible infusion format would reinforce those advantages.

What licensing deals could create commercial opportunities?

The most attractive licensing targets are not necessarily new excipients. They are enabling technologies that improve delivery, storage, or administration.

High-value licensing targets

Potential partners include:

• Infusion-bag manufacturers with multilayer non-PVC systems.
• Prefilled syringe and dual-chamber device companies.
• Specialty excipient suppliers with injectable-grade buffers or stabilizers.
• Contract development and manufacturing organizations experienced in colloidal iron products.
• Pharmacy automation companies.
• Infusion pump manufacturers.
• Regional generic manufacturers with established sterile injectable capacity.

A licensing package could include formulation composition, manufacturing process, container closure, device integration, and regional rights. The strongest deal structure would link milestones to stability, scale-up, regulatory approval, and commercial launch rather than licensing an excipient in isolation.

How strong is the Monoferric patent estate?

The estate is strategically stronger at the drug-substance and manufacturing levels than at the basic excipient level. The marketed formulation uses a limited excipient set, so a competitor may avoid a narrow formulation claim by using a different tonicity system or packaging configuration.

Patent strength can be assessed across four layers:

Layer	Strategic strength	Reason
Ferric derisomaltose drug substance	High	Complex active ingredient and difficult-to-reproduce attributes
Manufacturing process	High to moderate	Process conditions may affect equivalence and quality
Basic sodium chloride formulation	Moderate to low	Simple excipient substitution may be possible
Delivery device and ready-to-infuse presentation	Moderate to high	Can create differentiated claims linked to stability and workflow

The most defensible new IP would combine excipient composition with a measurable technical benefit. Broad claims covering only water, sodium chloride, or a generic infusion bag would face greater validity and design-around risk.

What revenue exposure does generic entry create?

Monoferric revenue is exposed to both direct substitution and class-level price pressure. A generic entrant could affect:

• Hospital formulary placement.
• Outpatient infusion-center purchasing.
• Group purchasing organization contracts.
• Net price and rebate levels.
• Pharmacosmos' negotiating leverage.
• Share of high-dose intravenous iron use.

A single generic may not cause immediate full substitution because hospitals may retain the branded product for supply reliability, established protocols, or complex-product confidence. Multiple ANDA approvals would create greater price pressure. A ready-to-infuse branded presentation could protect part of the commercial base by shifting competition from active ingredient price to total administration cost.

What are the best commercial opportunities for excipient suppliers?

The clearest opportunities are:

1. Injectable-grade stabilizer or buffer systems validated for ferric derisomaltose.
2. Non-PVC infusion bags with demonstrated iron compatibility.
3. Dual-chamber or ready-to-infuse packaging.
4. Prefilled transfer syringes and closed-system devices.
5. Excipient-container combinations that extend post-dilution stability.
6. Analytical services for labile iron, particle burden, and complex integrity.
7. Contract manufacturing of ferric derisomaltose presentations.
8. Regional licensing of differentiated formulations.
9. Pharmacy workflow products that reduce dilution and handling.
10. Generic-development support focused on complex injectable equivalence.

The highest-value opportunity is an integrated formulation and delivery system that reduces preparation steps while preserving Monoferric's high-dose positioning.

Key Takeaways

• Monoferric contains ferric derisomaltose at 100 mg elemental iron/mL with water for injection and sodium chloride as the principal listed excipients.[1]
• Conventional excipient substitution has limited value because the marketed formulation is already simple.
• Ready-to-infuse bags, dual-chamber systems, extended post-dilution stability, and infusion-device compatibility offer stronger commercial differentiation.
• The principal IP barriers relate to the ferric derisomaltose complex and its manufacturing process, not basic sodium chloride use.
• Monoferric is a non-biologic drug, so biosimilar competition is not the relevant risk category.
• Generic entry would likely require a technically demanding ANDA strategy focused on complex injectable equivalence.
• A formulation-device combination is more commercially defensible than a standalone excipient change.
• The current Orange Book, USPTO records, FDA approval materials, and litigation filings should control any final launch-date or patent-expiry conclusion.[1-4]

FAQs

Can Monoferric be reformulated with phosphate buffer?

Phosphate should not be assumed to be compatible with an iron-carbohydrate complex. A phosphate formulation would require comparative testing for precipitation, iron release, particle formation, pH drift, and long-term stability.

Is a ready-to-use Monoferric infusion commercially differentiated?

Yes. A ready-to-use bag could reduce pharmacy preparation, dilution errors, handling time, and waste. The primary requirements are post-dilution stability, container compatibility, sterility assurance, and regulatory support.

Can an excipient change avoid Monoferric's patents?

Possibly for narrow formulation claims, but an excipient change would not necessarily avoid patents covering ferric derisomaltose, its manufacture, or method of use. Freedom-to-operate analysis must evaluate every relevant claim category.

Would a generic Monoferric need clinical trials?

The requirement depends on FDA's applicable product-specific standards and the applicant's equivalence package. Complex injectable products can require more extensive comparative characterization and clinical or pharmacodynamic evidence than conventional small molecules.[4]

Which container is most attractive for a Monoferric follow-on product?

A non-PVC multilayer infusion bag is commercially attractive because it can support a ready-to-infuse format and reduce preparation steps. Its suitability depends on adsorption, extractables and leachables, iron recovery, particulate control, and stability data.

References

1. U.S. Food and Drug Administration. (2024). Monoferric (ferric derisomaltose) injection, prescribing information. Pharmacosmos Therapeutics Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. United States Patent and Trademark Office. (2025). Patent Center and Patent Term Adjustment resources. USPTO.

4. U.S. Food and Drug Administration. (2023). Product-specific guidances for generic drug development. FDA.